Eisai announced the appointment of Thomas D. Fagan Jr. as VP of US Alzheimer's Disease Commercial. In this role, he will be responsible for leading the development and implementation of the commercial launch strategy for the company's Alzheimer's disease (AD) business in the United States, as well as accelerate the growth and expansion of the AD team. He will also serve as a member of the company's Executive Committee for the Americas. The appointment comes at an exciting time for the company as Eisai continues to advance a robust AD pipeline.
Mr. Fagan joins Eisai with an extensive leadership background and strong record in driving business results. In his new position, he will work closely with internal teams and Eisai's partners to prepare for the potential launch and growth of a late-stage investigational anti-amyloid protofibril antibody. To fulfill our company's mission to best serve patients and their families, key responsibilities will include continuing to build and sustain trust with stakeholders across the AD community, pursuing new innovations to simplify the patient journey, and ensuring broad access for appropriate patients to benefit from potential new therapies.
"For four decades, Eisai has been at the forefront of AD research and development. We are very pleased to welcome Tom, whose knowledge and experience in AD will be essential as we seek to bring leading therapies and solutions to people living with AD, their families, and the health care professionals who serve them as soon as possible," said Ivan Cheung, Chairman & CEO of Eisai Inc., Global Alzheimer's Disease Officer, and Senior Corporate Officer, Eisai Co., Ltd. "Tom is the latest strategic hire as Eisai continues to add to our strong U.S. executive team in an effort to advance our human health care mission and social good."
Mr. Fagan joins Eisai with more than 20 years of experience serving the pharmaceutical, medical device and diagnostics industries during which time he accumulated roles of increasing responsibility across product and brand development, commercialization, business development and alliance management including seven years in roles dedicated to AD. He has held the role of Global Commercial Leader, Alzheimer's Disease, where he designed, built and led commercial teams in the launch of a first-in-class PET radiopharmaceutical used in the diagnosis of AD. He also served as the Global Brand Development Leader for AD, in which he was the commercial lead for an alliance on a late-stage molecule for the treatment of early AD. Mr. Fagan earned his Master of Business Administration (MBA) degree in general management from Stanford University and holds a Bachelor of Arts degree in Economics from DePauw University, where he graduated summa cum laude and was a member of Phi Beta Kappa.
Eisai's comprehensive investigational dementia pipeline includes disease modification and prevention compounds spanning the continuum of dementia: Amyloid, Tau, Neurodegeneration and Neuroinflammation (ATN).
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!